Temporal patterns of neurostimulation efficacy in drug-resistant epilepsy: A systematic review and meta-analysis.

Brain Res BullJun 16, 2026 (epub)
Clinical ResearchNeurology

Yiran Tian, Zhirong Wei, Tinghong Liu et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the efficacy of four neurostimulation modalities in patients with drug-resistant epilepsy. A total of 94 cohorts were analyzed, revealing responder rates of 38.7% at 3 months, increasing to 61.8% at ≥21 months. The study confirmed a significant time-dependent improvement in efficacy across all modalities, although no statistical evidence indicated differing trajectories among them.

Key findings

  • Responder rates improved from 38.7% at 3 months to 61.8% at ≥21 months.
  • Meta-regression showed a significant main effect for follow-up duration (Q M = 96.3, p < 0.0001).
  • Numerical differences in efficacy among devices were attributed to patient selection rather than hardware superiority.

Why it matters

Understanding the temporal patterns of neurostimulation efficacy can guide clinicians in setting realistic expectations for patients with drug-resistant epilepsy. The progressive improvement over time highlights the potential for long-term benefits from these interventions.

Source

Published in Brain Res Bull. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.